CTOs on the Move

Bausch + Lomb

www.bausch.com

 
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New ...
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion
  • www.bausch.com
  • 400 Somerset Corporate Boulevard
    Bridgewater, NJ USA 08807
  • Phone: 866.246.8245

Executives

Name Title Contact Details
Peter Fourie
SVP, Chief Information Officer Profile
Manisha Narasimhan
Chief Corporate Development and Digital Officer Profile
Charles Frahm
Executive Director and Chief Security Officer, Bausch and Lomb Profile

Similar Companies

Falks Woodland Pharmacy

Falks Woodland Pharmacy is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agrios Global Holdings

Agrios Global Holdings Ltd. operates as a holding company. The Company, through its subsidiaries, provides aeroponic equipment rental, nutrient procurement, monitoring, and agronomy consultancy services. Agrios Global Holdings serves customers in Canada.

Heron Therapeutics

Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which SUSTOL and its other products are based, consists of bioerodible polymers designed to release drugs over a defined period of time. The Company has completed over 100 in vivo and in vitro studies demonstrating that its Biochronomer technology is potentially applicable to a range of therapeutic areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. Heron Therapeutics has also completed comprehensive animal and human toxicology studies that have established that its Biochronomer polymers are generally well tolerated. Furthermore, the Company's Biochronomer technology can be designed to deliver drugs over periods varying from days to several months. In addition to its lead drug candidate SUSTOL, Heron Therapeutics has a pipeline of other product candidates that use the Biochronomer technology.  

Vinta Bio

VintaBio is a life sciences company that specializes in customized process development, GMP manufacturing, and quality control services for cell and gene therapies.

STERIS IMS

STERIS Instrument Management Services is a surgical device and instrument management and consulting company.